Interferon-αα in high-risk melanoma patients

Authors: Cormier, Janice N; Xing, Yan; Ross, Merrick I; Cantor, Scott B

Source: Expert Review of Pharmacoeconomics and Outcomes Research, Volume 4, Number 6, December 2004 , pp. 667-676(10)

Publisher: Expert Reviews

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

The incidence of melanoma has been climbing steadily since the early 1970s. Although melanoma can be successfully cured by surgical excision in its early stages, it is the most common fatal form of skin cancer. The most critical factors in determining the prognosis for patients with melanoma are primary tumor thickness, ulceration and the status of regional lymph nodes. Surgical treatment alone is inadequate in patients with thick, ulcerated tumors and those with nodal disease, as shown by poor 5-year disease-specific survival rates. Despite the fact that high-dose interferon-αα has been approved for the treatment of high-risk melanoma by the US Food and Drug Administration and regulatory agencies worldwide, current treatment recommendations vary widely due to the conflicting trial data and significant toxicity and cost associated with high-dose interferon-αα.

Keywords: cost effectiveness; interferon-αα; melanoma

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14737167.4.6.667

Publication date: 2004-12-01

More about this publication?

Expert Review of Pharmacoeconomics & Outcomes Research provides expert commentary on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites